The expert dermatologist examined how patient-specific factors drive JAK inhibitor selection, with baricitinib favored for patients who prioritize an established long-term safety record, ritlecitinib ...
Author contribution: idea, design, literature search, preparation of the manuscript, approval of the version of the manuscript submitted. Ayyad Zartasht Khan PhD, specialty registrar in the Department ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results